Bolt Biotherapeutics, Inc. (BOLT)
NASDAQ
4.31
+0.27 (+6.68%)
Closed
Oct 20, 2026
Day's Range
4.054.33
52 wk Range
3.107.20
Financial Statements - BOLT - Bolt Biotherapeutics, Inc.
Revenue
7.69M▲ 0.1%
Net Income
-33.37M▲ 47.1%Net Margin -433.7%
EBITDA
-31.86M▲ 48.3%
Free Cash Flow
-39.92M▲ 34.9%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 7.69M | 7.69M | 7.87M | 5.72M | 1.26M | 231K |
| Cost of Goods | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -34.63M | -68.23M | -76.19M | -90.32M | -92.78M | -49.18M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -1.23M | -137K | - | - | -6.08M | -11.74M |
| Pre Tax Income | -33.37M | -63.11M | -69.19M | -88.09M | -98.59M | -60.72M |
| Income Tax | - | - | - | - | - | - |
| Net Income | -33.37M | -63.11M | -69.19M | -88.09M | -98.59M | -60.72M |
| EPS Basic | -17.85 | -33 | -1.83 | -2.36 | -2.97 | -1.906885 |
| EPS Diluted | -17.85 | -33 | -1.83 | -2.36 | -2.97 | -1.906885 |
| Basic Shares Outstanding | 1.86M | 1.90M | 37.81M | 37.35M | 33.19M | 31.84M |
| Diluted Shares Outstanding | 1.86M | 1.90M | 37.81M | 37.35M | 33.19M | 31.84M |
| Ebit | -34.63M | -68.23M | -76.19M | -90.32M | -92.78M | -49.18M |
| Ebitda | -31.86M | -61.64M | -74.34M | -88.65M | -85.51M | -36.82M |
| Net Income Continuous Operations | -33.37M | -63.11M | -69.19M | -88.09M | -98.59M | -60.72M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
